World’s largest society for regulatory professionals increases investment in Europe
An investment of more than 2 million euro over 3 years is planned to launch new events and resources.
The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products.
In the last 12 months, the largest global organisation for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has seen its European member base grow by approximately 19% to more than 1,500 members across 29 countries.
RAPS plans to invest more than 2 million euro over 3 years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region.
RAPS executive director Paul Brooks said: “Europe has a vibrant and progressive healthcare products community and many of our existing regulatory professionals are working here, so increasing our investment in Europe was a natural next step for RAPS.
“Healthcare is a global business, and with more than 15,000 members in over 80 countries, we are well aware of the challenges regulatory professionals face worldwide. Our own research has shown that in Europe more than 65% of professionals in the healthcare product industries have multi-regional or worldwide responsibilities,” said Brooks. “RAPS is committed to understanding the specific needs of European regulatory professionals and supporting our local chapters and networks.”
The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on 4 and 5 July in Brussels.
Brooks continued: “In highly regulated environments such as the pharmaceutical and medical device sectors, there is a greater need than ever for regulatory professionals to stay up to date on the latest regulatory developments. In particular, changes to medical device regulations in Europe present a huge challenge to manufacturers and should be high on the industry’s agenda as we move towards the 2020 deadline.”
In addition to in-person events, RAPS will host a four-part virtual programme in May, ‘Understanding the New EU Medical Device and IVD Regulations’ and has produced a helpful ‘interactive guide’ to the new EU Medical Device and IVD Regulations.
As part of its investment in Europe RAPS is also looking to increase awareness of its Regulatory Affairs Certification (RAC). The RAC is the only professional certification specifically for those in the healthcare product regulatory field, testing knowledge and critical thinking relating to the international practice of regulatory affairs. Four RAC credentials are available, including one focused on European regulations. Currently, more than 4,000 individuals around the world are RAC-credentialed.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.